HHC products - what are they and are they safe? Guide 2026

HHC, or hexahydrocannabinol, was sold in Poland in "legal highs" stores as a supposedly safe alternative to THC just three years ago. On July 17, 2023, the Minister of Health added HHC and its derivatives to the list of narcotic drugs of the IN group (Journal of Laws 2023 item 1232). From that day on, anyone who produces, sells, or possesses HHC is breaking the law on counteracting drug addiction.

According to the EMCDDA Annual Report 2024, HHC was detected in 22 EU member states between May 2022 and September 2023, and the number of reported acute poisonings in European toxicology centers more than doubled year-on-year (EMCDDA Annual Report 2024). This isn't "light recreation." It's an untested, semi-synthetic compound with a risk profile similar to other synthetic cannabinoids.

In this guide, we explain the pharmacology of HHC, its legal status in Poland 2026, the mechanism of formation through hydrogenation of THC, as well as the real risks reported by EMCDDA, ACMD UK, and NIDA. We show why HHC appeared on the market and point out safe, legal alternatives: natural CBG and CBD derived from industrial hemp Cannabis sativa L.

KEY INFORMATION
– HHC is a semi-synthetic cannabinoid produced by catalytic hydrogenation of delta-9-THC, not a natural hemp extract.
– From July 17, 2023, HHC, HHC-O and HHC-P are included in the list of narcotic drugs of group IN in Poland (Journal of Laws 2023 item 1232). Production, possession, and trade are prohibited.
– HHC acts as a partial CB1 agonist, producing psychoactive effects, tachycardia, anxiety and paranoia comparable to THC, and in some users even stronger.
– No long-term clinical studies in humans. EMCDDA and NIDA classify HHC as a high-risk substance (EMCDDA, 2024).
– Natural CBG and CBD from hemp are legal, non-addictive and have a documented safety profile according to WHO (2018).

What is HHC and where did it come from on the market?

HHC, or hexahydrocannabinol, is a semi-synthetic cannabinoid obtained by hydrogenating the double bond in the delta-9-THC molecule. The first synthesis was described by Roger Adams in 1944 in the Journal of the American Chemical Society. Commercially, HHC appeared only in 2021 in the USA, and in 2022 in Europe (EMCDDA Annual Report 2024).

The rise in popularity of HHC was not coincidental. After the adoption of the 2018 Farm Bill in the USA, which legalized hemp with THC below 0.3%, a legal loophole emerged. Producers exploited cheap CBD surpluses from industrial hemp as raw material for synthesizing new cannabinoids. CBD was first converted into THC and then through hydrogenation into HHC, formally bypassing the legal control of delta-9-THC.

The structure of HHC itself occurs in the cannabis plant in trace amounts, below 0.01% of the dry weight of the flower. Practically all commercially available HHC comes from laboratory synthesis. The starting material is hemp-derived CBD, a high-pressure reactor, a metal catalyst (palladium or Raney nickel), and hydrogen. This is an industrial process, not extraction from the plant.

Roger Adams and historical background

HHC was first synthesized 80 years ago, but for decades it remained a laboratory curiosity. Adams worked on understanding the chemistry of cannabinoids at a time when the structure of THC was still unclear. Commercial interest only emerged when producers began looking for ways to circumvent THC regulations.

Between 2021 and 2023, the HHC market exploded. EMCDDA reported the detection of HHC in products from 22 EU countries: in disposable vapes, flowers, gummies, oils, and herbal mixtures (EMCDDA Annual Report 2024). Poland reacted relatively quickly, introducing a ban in July 2023.

Why HHC is not a "natural cannabinoid"„

This distinction has both chemical and legal significance. Natural cannabinoids (CBD, CBG, CBN, THC) are biosynthetically produced in the plant from the precursor CBGA. HHC is produced exclusively under laboratory conditions, in the presence of metal catalysts. It is classified as semi-synthetic because the raw material comes from the plant, but the final molecule is produced in a reactor.

Manufacturers often advertise HHC as "natural," which is misleading. Forensic Science International, in its analysis of HHC products from the European market, detected the presence of metal catalyst residues and unreacted precursors (Forensic Science International, 2023). It is a chemical product, not a plant-based one.

How is HHC produced? The hydrogenation process of THC

HHC is produced by catalytic hydrogenation of delta-9-THC or delta-8-THC. The process requires a pressure of 50-100 bars, a temperature of 60-100 degrees Celsius, gaseous hydrogen, and a metal catalyst, most often palladium on carbon or Raney nickel (Cannabis and Cannabinoid Research, 2022). The reaction converts the double bond in the cyclohexene ring of THC into a single bond, adding two hydrogen atoms.

The effect of hydrogenation is to saturate the molecule. Hence the name hexahydro – six hydrogen atoms resulting from the structure's saturation. The molecule loses a cyclohexene ring and gains a cyclohexane ring. This change seems subtle, but it has significant pharmacological consequences. The product is not a single molecule, but a mixture of two isomers.

Two epimers are formed: 9R-HHC and 9S-HHC. They differ only in the spatial orientation of the methyl group at carbon C9. 9R-HHC has significant affinity for the CB1 receptor and induces psychoactive effects. 9S-HHC has much weaker affinity and is practically inactive psychoactively. The ratio of epimers in the final product ranges from 1:1 to 4:1 R:S, depending on the synthesis conditions.

Purity of HHC products from the market

Forensic Science International examined 24 samples of HHC products from the EU market in 2023. Only 8 samples contained HHC in the declared amount. The others had discrepancies from 30% to 200% compared to the label, and some contained trace amounts of delta-9-THC and metal catalyst residues (Forensic Science International, 2023). This level of contamination is unprecedented in legal pharmacy.

Based on our market observations from 2022 to 2023, before the ban was introduced, most HHC products in Polish drug stores lacked COAs, and the declared substance content was impossible to verify. After July 2023, these products disappeared from the legal market, but some entered the gray market.

Difference from natural cannabinoids

Natural CBG, CBD, or CBN are produced in the flower cells of cannabis with the participation of synthase enzymes. This is a stereospecific process: plants produce only one biologically active isomer. The chemical synthesis of HHC is not stereospecific, which is why it yields a mixture of epimers with an unpredictable action profile.

Additionally, the hydrogenation process may not be complete. Underhydrogenated THC precursors may remain in the final product. This is one reason why some HHC users report stronger effects than "classic" THC. In reality, they may be exposed to a mixture of several cannabinoids in unknown proportions.

HHC is produced by catalytic hydrogenation of delta-9-THC in the presence of palladium or Raney nickel, resulting in a mixture of two epimers 9R-HHC (active) and 9S-HHC (practically inactive) in a ratio of 1:1 to 4:1 (Cannabis and Cannabinoid Research, 2022). This variability explains the unpredictability of the body's reaction to HHC products from the market.

Pharmacological profile of HHC: partial agonist of CB1

HHC acts as a partial agonist of the CB1 receptor, similar to delta-9-THC. The active epimer 9R-HHC has an affinity for CB1 about 2-3 times weaker than THC, but sufficient to induce psychoactive effects (Cannabis and Cannabinoid Research, 2022). The CB1 receptor is mainly located in the central nervous system, in the hippocampus, cerebellum, and prefrontal cortex.

CB1 activation causes known psychoactive effects. Euphoria, short-term memory impairment, slowed reaction time, impaired motor coordination, and increased heart rate. Subjectively, some users describe HHC as "milder than THC," but EMCDDA data show a similar number of reports of acute poisoning per exposure (EMCDDA, 2024).

HHC also affects the CB2 receptor present in immune system cells. Its affinity for CB2 is weaker than for CB1, but sufficient to modulate the inflammatory response. This distinguishes HHC from CBD, which primarily acts indirectly by modulating endogenous anandamide and 5-HT1A receptors.

Duration of action and metabolism

After inhalation, the effect of HHC appears in 2-10 minutes, peaks after 30-60 minutes, and lasts 3-6 hours. After oral administration, the effect begins after 30-90 minutes, peaks after 2-3 hours, and lasts up to 8 hours. These ranges are similar to delta-9-THC.

The metabolism of HHC occurs in the liver, mainly through cytochrome P450 enzymes (CYP2C9, CYP3A4). Hydroxylated metabolites are produced, including 11-hydroxy-HHC, which is itself psychoactively active. Metabolites are excreted in urine for 1-3 weeks after the last dose, which is significant for drug testing.

Cross-reactivity with THC tests

HHC and its metabolites cause cross-reactivity with immunoenzymatic tests for THC. Forensic Science International reported cases of positive test results in drivers using only HHC (Forensic Science International, 2023). This poses a significant legal risk, as in Poland, a driver with a positive THC test commits an offense under Article 178a of the Penal Code.

Forensic laboratories are increasingly expanding panels to include specific markers for HHC, but routine test strips do not distinguish HHC from THC. From the perspective of a professional driver or someone working in a field requiring testing (sports, transport, aviation), the legal and professional risks are real.

Legal status of HHC in Poland in 2026

HHC has been banned in Poland since July 17, 2023. The regulation of the Minister of Health of June 30, 2023, amending the regulation on the list of new psychoactive substances added HHC and its derivatives to group I-N narcotic substances (Journal of Laws 2023 item 1232). This status remains unchanged in 2026.

The legal consequences of possessing HHC are significant. Possessing even a small amount is a crime punishable by up to 3 years in prison (Article 62 of the Act on Counteracting Drug Addiction). Introducing it into circulation is punishable by 6 months to 8 years. Producing significant amounts carries a penalty of 3 to 15 years in prison (Journal of Laws 2005 No. 179 item 1485).

The ban also covers HHC derivatives, including HHC-O and HHC-P. The list uses a broad definition, encompassing stereoisomers and structural derivatives. This is a deliberate legislative measure intended to prevent attempts to circumvent the ban through minor modifications to the molecule, as previously happened with synthetic "Spice" cannabinoids.

What about old stocks?

Possessing HHC purchased before the ban came into effect does not exempt one from criminal liability. After July 17, 2023, anyone possessing HHC, regardless of the purchase date, commits an offense. The safest step is to return remaining stocks for disposal at a local pharmacy or police station.

Stores that legally sold HHC before the ban were required to withdraw the products from circulation and dispose of them. The Sanitary Inspectorate and the Police conducted inspections during the transition period. Today, HHC products are not legally available – anyone offering such products is operating in a gray area and risks criminal liability.

Consequences for drivers

HHC causes psychomotor impairment comparable to THC. In Poland, driving under the influence of a narcotic substance is a crime under Article 178a §1 of the Penal Code, punishable by up to 3 years in prison and a mandatory driving ban. Cross-reactivity with immunoenzymatic tests for THC means that even a driver who has not used THC but only HHC may receive a positive result on a roadside test.

Status of HHC in the European Union and EMCDDA monitoring

EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) has been monitoring HHC since 2022 as part of the early warning system for new psychoactive substances. According to the 2024 report, HHC was detected in 22 EU member states, and the number of reports of serious adverse events after HHC increased from 8 in 2022 to over 30 in 2023 (EMCDDA Annual Report 2024).

Member states respond differently. France, Austria, Finland, Estonia, and Belgium introduced HHC bans in 2023. Germany banned HHC in June 2023, and the UK (outside the EU) implemented control under the Misuse of Drugs Act 1971 through ACMD. Poland introduced a ban in July 2023, shortly after Germany and France.

Some EU countries still lack clear regulations. There, HHC is sold officially, but regulatory pressure is increasing. As part of the work on Regulation 2017/2101 on new psychoactive substances, the European Commission is considering harmonizing the HHC ban across the EU. A decision at the EU level may be made in 2026 or 2027.

ACMD UK and British classification

The Advisory Council on the Misuse of Drugs (ACMD) in 2023 recommended classifying HHC and its analogs as controlled substances. The ACMD report indicated that HHC-P, one of the HHC analogs, has significantly higher affinity for CB1 than THC, making it potentially more dangerous (ACMD UK, 2023). The recommendations were implemented through an amendment to the Misuse of Drugs Act.

NIDA (National Institute on Drug Abuse) in the USA is tracking the development of the HHC market, but the federal legal status of HHC remains unclear. Some US states have introduced state bans (Colorado, Washington, Oregon, Utah), while others have left HHC in the gray market. This is not a model to follow, but rather an example of a regulatory gap that Europe closed more quickly.

HHC-O and HHC-P: synthetic derivatives

HHC-O (HHC acetate, hexahydrocannabinol acetate) and HHC-P (hexahydrocannabiforol) are semi-synthetic derivatives of HHC that have appeared on the market as an attempt to circumvent the legal control of HHC. According to ACMD UK (2023), HHC-P has an affinity for the CB1 receptor even 13-30 times higher than delta-9-THC, making it one of the strongest synthetic cannabinoids available on the black market.

HHC-O is produced by acetylating HHC with acetic anhydride. This modification increases the lipophilicity of the molecule and is said to enhance its bioavailability. However, there are no reliable pharmacokinetic studies. EMCDDA warns that HHC-O induces stronger psychoactive effects than HHC, with serious adverse events reported more frequently.

HHC-P has an extended alkyl chain: 7 carbon atoms instead of 5 as in HHC and THC. This "trick" is known from THCP, a cannabinoid naturally occurring in trace amounts. The extended chain dramatically increases its affinity for CB1. In Poland, HHC-P and HHC-O are subject to the same ban as HHC as of July 2023 (Journal of Laws of 2023, item 1232).

Why derivatives are more dangerous than HHC

The stronger the CB1 agonist, the greater the risk of acute intoxication. Classic THC has a "natural" safety margin: the dose that produces euphoria is significantly lower than the toxic dose. HHC-P violates this safety margin. Given the unknown content in the final product, the user can easily exceed the safe dose.

The EMCDDA has reported cases of serious cardiac events in young people using HHC-P. Tachycardia above 150 beats per minute, acute coronary syndrome, and syncope have been reported. This is not a "mild alternative to marijuana"; these substances have a profile closer to the synthetic cannabinoids from the SCRA group, known from 2010-2015 ("Spice," "K2").

Risks and side effects of HHC

NIDA, EMCDDA, and Forensic Science International consistently point to the high risk associated with HHC use. The most commonly reported side effects are tachycardia (excessive heart rate), anxiety, paranoia, dry mouth, dizziness, nausea, and coordination disturbances. EMCDDA noted an increase in reports of acute HHC poisonings in EU countries of over 200% between 2022 and 2023 (EMCDDA Annual Report 2024).

The risk profile of HHC includes four main areas. The first is the cardiovascular system. HHC raises heart rate, sometimes above 130-150 beats per minute. In individuals with hypertension, coronary artery disease, or arrhythmia, this poses a risk of acute incidents. The second area is mental health. Anxiety, paranoia, panic attacks, and disorientation occur particularly frequently in novices or at higher doses.

The third area is psychomotor safety. HHC impairs coordination, reaction time, and distance assessment. Driving, operating machinery, and working at heights are all dangerous activities under the influence of HHC. The fourth area is interactions with medications and substances. HHC combined with alcohol or benzodiazepines intensifies central nervous system depression.

List of the most common side effects

According to toxicological reports from EMCDDA and case descriptions in Forensic Science International (2023), HHC users report the following side effects:

Tachycardia – heart rate increases above 100, sometimes above 150 beats per minute.
Anxiety, paranoia, disorientation – especially with first exposures or higher doses.
Dry mouth and eyes – classic effect of cannabinoid agonists.
Dizziness, nausea, vomiting – especially after oral administration of a larger dose.
Impairment of short-term memory – loss of thread, difficulty remembering conversations.
Motor coordination disturbances – risk of falls and accidents.
Drowsiness or insomnia – dose-dependent and sensitivity-dependent reaction.
Psychotic reactions – rare, but described, more common in people with predispositions.

Risk of addiction

HHC, like other CB1 agonists, has addictive potential. Tolerance builds quickly. After a few weeks of regular use, the same dose produces a weaker effect, leading users to increase the amount. Withdrawal syndrome includes irritability, insomnia, loss of appetite, anxiety, and depression. Withdrawal symptoms appear 1-3 days after cessation and can last 2-4 weeks.

NIDA classifies synthetic cannabinoids as substances with significant addictive potential. HHC falls into this group, although epidemiological data is still limited (NIDA, 2024). The lack of long-term clinical studies means we do not know the full extent of the problem.

Risk of contamination

Forensic Science International detected residues of metal catalysts (palladium, nickel), unreacted precursors (delta-9-THC, delta-8-THC), organic solvents, and unknown by-products of the reaction in HHC products from the EU market (Forensic Science International, 2023). Each of these contaminants poses potential additional health risks, not directly related to the pharmacology of HHC.

The number of reported acute HHC poisonings in European toxicology centers increased from 8 in 2022 to over 30 in 2023, and HHC was detected in 22 EU countries between May 2022 and September 2023 (EMCDDA Annual Report 2024). This is the scale that justifies treating HHC as a high-risk substance rather than a "mild alternative to THC.".

Lack of long-term clinical studies

According to NIDA and EMCDDA, there are no long-term clinical studies on the use of HHC in humans. All available data comes from case descriptions, toxicological reports, in vitro studies, or animal models (EMCDDA, 2024). This is a fundamental difference from CBD, for which there are phase III clinical studies and an FDA and EMA accredited drug, Epidiolex.

The lack of data particularly concerns key areas. The impact on the cardiovascular system with regular exposure. The impact on the liver with long-term metabolism. The impact on mental health, including the risk of schizophrenia in predisposed individuals. The impact on fertility, pregnancy, and child development. The impact on memory and executive functions with years of exposure.

The standard drug approval process requires years of clinical studies in phases I, II, and III, involving thousands of patients. HHC has not passed any of these stages. It is a market product without scientific verification of safety. The manufacturer bears no responsibility for health consequences, as the product is not sold as a drug or supplement.

What do we know from preclinical studies

In vitro and animal studies show that HHC acts on CB1 and CB2 receptors, is metabolized by the liver, excreted by the kidneys, and exhibits some cellular toxicity at high concentrations. These data are insufficient to assess safety in humans under real use conditions.

Cannabis and Cannabinoid Research published a review of available pharmacological data on HHC in 2022. The authors conclude: "There is a lack of adequate clinical data. Any commercial use of HHC is without a scientific basis for safety" (Cannabis and Cannabinoid Research, 2022). This is the position of one of the most cited journals in the field of cannabinoids.

Why did HHC appear on the market?

HHC wasn't created out of medical or scientific necessity. It emerged as a response to a loophole in the 2018 US Farm Bill, which federally legalized hemp with THC below 0.31 TP3T. CBD producers had a massive surplus of the raw material, the price of which plummeted several times between 2019 and 2021. HHC became a way to "increase the value" of this raw material.

The business model was simple: CBD was chemically converted to delta-9-THC (artificial isomerization) and then hydrogenated to HHC. The final product was psychoactive, but not technically "delta-9-THC," so producers believed it was beyond regulatory scrutiny. This interpretation was disputed in many jurisdictions, but it allowed the market to develop for a time.

The second reason is consumer demand. Some people in countries where THC is illegal sought legal alternatives. Marketing for THC relied on the promise of "similar effects to marijuana, but legal." This promise was short-lived, as most EU countries closed the legal loophole within 12 to 18 months.

Regulatory lesson

HHC demonstrated how quickly the illicit drug market adapts to regulations. Following the HHC ban, HHC-O, HHC-P, THCP, THCJD, and other derivatives emerged. This is an "arms race" between producers and regulators. Poland and several other EU countries responded with broad definitions banning "all derivatives" rather than individual molecules, making it more difficult to circumvent the law.

From the consumer's perspective, each new untested molecule emerging as an "alternative" poses a greater risk than the last. Manufacturers are shortening the cycles for introducing new substances, meaning less and less time for safety testing. This is a trend the EMCDDA describes as the "designer cannabinoid arms race" and is one of its top monitoring priorities.

Natural, legal alternatives: CBG and CBD

According to a 2018 WHO review, CBD is "generally well tolerated in humans" and does not present any addictive potential or significant risk of abuse. The Polish CBD market is estimated at approximately €130 million in 2024, with a CAGR for the CBG segment of 16.21 TP3T by 2030 (Fortune Business Insights, 2024). This is a mature, regulated market with a documented safety profile.

CBG (cannabigerol) and CBD (cannabidiol) are natural, non-psychoactive cannabinoids found in industrial hemp Cannabis sativa L. They are biosynthetically produced in the plant from the precursor CBGA. They do not strongly activate the CB1 receptor, so they do not induce psychoactive effects. They act by modulating endogenous anandamide, 5-HT1A receptors, alpha-2 adrenergic, and vanilloid TRPV1.

Both compounds are legal in Poland if derived from industrial hemp with THC content below 0.3% (Journal of Laws 2005 No. 179 item 1485). They are not listed as controlled substances. They are sold as cosmetics, botanical extracts, or wellness products. They have a documented safety profile, unlike HHC.

How do CBG and CBD differ from HHC?

The first difference is origin. CBG and CBD come from a plant, HHC from a chemical reactor. The second difference is psychoactivity. CBG and CBD don't cause a "high," HHC does. The third difference is legality. CBG and CBD are legal in Poland, HHC has been banned since 2023. The fourth difference is research. CBD has had Phase III clinical trials, CBG has had dozens of publications, and HHC has had virtually no clinical trials in humans.

The fifth difference is addictive potential. WHO assessed CBD as devoid of addictive potential (WHO, 2018). HHC, like other CB1 agonists, has addictive potential comparable to THC. The sixth difference is predictability. Natural cannabinoids have a stable, described pharmacological profile. HHC from the market is a mixture with variable content and unknown contaminants.

When to choose CBD and when CBG?

CBD is effective in supporting sleep, reducing nervous tension, recovering from exercise, and relieving daily stress. It's a "nighttime" cannabinoid, calming and modulating the endocannabinoid system toward homeostasis. Typical adult doses are 20-50 mg daily, divided into 2-3 doses, administered sublingually. The full effect develops over 2-4 weeks of regular use.

CBG has a more "focusing" profile. The 2021 Cannabis and Cannabinoid Research survey included 127 CBG users. 51% reported improved concentration, 45% reduced muscle tension, 39% better sleep quality (Cannabis and Cannabinoid Research, 2021). CBG is usually taken in the morning, in doses of 15-30 mg. It pairs well with coffee and does not induce the drowsiness typical of higher doses of CBD.

Often, the best effects come from a combination of both cannabinoids in broad-spectrum oil, enhanced by the entourage effect from natural terpenes. Project CBD states that 62% of regular cannabinoid users choose combined products rather than isolates (Project CBD, 2023).

From the perspective of a cannabis shopper, we see a similar path for many people. First, trying HHC while it was still "legally available." Then, being surprised by the ban in 2023. Finally, discovering natural CBG and CBD as a stable, legal, and predictable wellness option. For most people, this path ends with broad-spectrum CBD 5-10%.

What to do if you have taken HHC?

If you have taken HHC and experience severe symptoms: tachycardia above 130, severe panic, shortness of breath, chest pain, loss of contact with reality, disorientation, fainting. Call 911 or go to the emergency room. These are not reactions to be "waited out." HHC can cause serious cardiac and psychiatric events requiring medical intervention.

Tell the medical staff what substance you took, in what dose, in what form (vaporization, orally, edibles), and when. Do not hide information. Medical confidentiality protects you, and knowledge of the substance will help in proper treatment. Remember that HHC can yield a positive THC test result, which is important for documentation.

For milder symptoms (anxiety, restlessness, tachycardia below 120), ensure a calm, dark, and quiet environment. Hydration, diaphragmatic breathing, contact with a trusted person. Do not combine HHC with alcohol or sedatives, as this intensifies central nervous system depression. Symptoms usually subside within 4-8 hours.

What next?

After an incident, consult your family doctor or an addiction specialist. If you took HHC thinking, "It's legal, therefore safe," now is a good time to reconsider that belief. HHC has been banned in Poland since 2023, and available preparations come from the gray market, with unknown quality and purity.

If you are looking for wellness support in the areas of stress, sleep, recovery, consider legal, natural CBG and CBD. These are products with a documented safety profile, purchased in stores with COA certificates, with no legal risk and no psychoactive effect. Consult your choice with a pharmacist if you are taking medications chronically.

Summary: HHC in 2026 is a dead end

HHC has been banned in Poland since July 17, 2023, as a narcotic substance of group I-N. Possession, production, and trade are subject to criminal liability under the Act on Counteracting Drug Addiction (Journal of Laws 2023 item 1232). HHC-O, HHC-P, and other derivatives are covered by the same ban. Products present in the gray market have unknown composition, active substance content, and contamination levels.

The risks are significant. Tachycardia, anxiety, paranoia, confusion, psychomotor impairment, risk of addiction, positive drug test results, and criminal liability. There are no long-term human clinical trials. The NIDA, EMCDDA, and ACMD UK all classify HHC as a high-risk substance. It is not a "mild alternative to marijuana.".

For those seeking legal wellness support, there are proven, natural alternatives. CBD and CBG from industrial hemp Cannabis sativa L. Non-psychoactive. Non-addictive (WHO, 2018). Compliant with Polish law with THC content below 0.3%. With a documented safety profile, COA certificates, and predictable pharmacology.

The choice seems obvious. A banned, untested, and potentially dangerous semi-synthetic substance versus natural cannabinoids with a stable profile and legal status. If you care about health and avoiding legal issues, natural CBG and CBD are the safe path.

Frequently Asked Questions

Is HHC legal in Poland in 2026?

No. HHC (hexahydrocannabinol) has been added to the list of narcotic substances of group I-N by the regulation of the Minister of Health from 2023 (Journal of Laws 2023 item 1232). Possession, production, and trade of HHC have been banned in Poland since July 17, 2023. Violation of the ban is prosecuted under the Act on Counteracting Drug Addiction.

What is the difference between HHC and THC?

HHC is produced by catalytic hydrogenation of delta-9-THC. The THC molecule has a double bond in the cyclohexene ring, which is saturated with hydrogen in HHC. Two epimers, 9R-HHC and 9S-HHC, are formed. Only 9R-HHC has significant affinity for the CB1 receptor (Cannabis and Cannabinoid Research, 2022). The market mixture contains both epimers in varying proportions.

Does HHC yield a positive drug test result?

Yes, in many tests, HHC and its metabolites cause cross-reactivity with immunoenzymatic tests for THC. Forensic Science International (2023) reported cases of positive results in drivers using HHC (Forensic Science International, 2023). Laboratories are increasingly expanding panels to include specific metabolites of HHC, so abstinence after a single dose should last at least 2-3 weeks.

What are the side effects of HHC?

The most commonly reported are tachycardia, anxiety, paranoia, dry mouth, dizziness, and coordination disturbances. EMCDDA Annual Report 2024 noted an increase in reports of acute HHC poisonings in EU countries of over 200% between 2022 and 2023 (EMCDDA, 2024). The risk profile is similar to other synthetic cannabinoids from the SCRA group.

What are HHC-O and HHC-P?

HHC-O (HHC acetate) and HHC-P (hexahydrocannabiforol) are semi-synthetic derivatives of HHC. HHC-P has an extended alkyl chain (7 carbon atoms) and according to ACMD UK (2023) shows significantly higher affinity for CB1 than THC (ACMD UK, 2023). Both substances appeared as an attempt to circumvent the legal control of HHC and are currently monitored by EMCDDA as new psychoactive substances.

Are there long-term safety studies on HHC?

No. NIDA and EMCDDA clearly indicate the lack of clinical studies on the long-term use of HHC in humans. Most available data comes from case descriptions, toxicological reports, and in vitro studies (NIDA, 2024). The lack of data particularly concerns the impact on the cardiovascular system, liver, and mental health with regular exposure.

Are CBG and CBD a safe alternative to HHC?

Yes. CBG and CBD are natural, non-psychoactive cannabinoids from industrial hemp Cannabis sativa L. WHO in its 2018 review assessed CBD as well tolerated in humans, with no addictive potential (WHO, 2018). Both compounds are legal in Poland with THC content below 0.3% (Journal of Laws 2005 No. 179 item 1485) and have a documented safety profile, unlike HHC.

What to do if I took HHC and feel unwell?

In case of severe tachycardia, shortness of breath, panic anxiety, or loss of contact with reality, call 112 or go to the emergency room. Tell the medical staff what substance you took, in what dose, and when. Do not mix HHC with alcohol or medications. After the incident, consult your family doctor or addiction specialist to verify further actions.

This article is for informational and educational purposes and does not constitute medical or legal advice. HHC, HHC-O, and HHC-P have been banned in Poland since July 17, 2023 (Journal of Laws 2023 item 1232). In case of acute symptoms after taking any psychoactive substance, call 112 or go to the emergency room. Before starting CBD or CBG supplementation, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027